Psoriatic Arthritis News

MADRID — According to findings presented at the EULAR Annual Congress, fatigue in patients with psoriatic arthritis was driven by inflammation, disease duration and chronic pain.

Nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis, with transverse grooves being a significant factor, according to recently published study results in the Journal of the American Academy of Dermatology.

MADRID — Secukinumab showed sustained improvements in patients with ankylosing spondylitis and in patients with psoriatic arthritis after 3 years, according to findings presented at the EULAR Annual Congress.

Among patients with psoriatic arthritis, biologics more often led to remission or minimal disease activity compared with conventional drugs, according to a published analysis.

MADRID — Patients with psoriatic arthritis and psoriasis had a similar prevalence of metabolic syndrome and hepatic stiffness, according to findings presented at the EULAR Annual Congress, here.

The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF biosimilar candidate to receive a positive opinion from the Committee for Medicinal Products for Human Use, the manufacturer announced.

MADRID — Inhibition of radiographic progression was independent of disease activity for adalimumab in patients with psoriatic arthritis, according to findings presented at the EULAR Annual Congress.

MADRID — Severe enthesitis on sonography was associated with radiographic peripheral and axial joint damage in patients with psoriatic arthritis, according to a study presented at the EULAR Annual Congress.

MADRID — In psoriatic arthritis patients initiating an adalimumab regimen, tumor necrosis factor-alpha inhibitor drug-level testing may have utility in determining 12-month treatment response and disability, according to findings presented at the EULAR Annual Congress.

Sexual dysfunction and intimacy issues may rank high among the complaints reported by patients with rheumatic diseases, but these complaints often remain unaddressed in the clinical setting, for several reasons. Poor communication between physicians and patients is the most likely explanation, along with poor communication between patients and their partners. However, the reasons for this communication gap, which may range from stigma to time constraints in the clinic, are up for debate.